This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk03: Focusing on what's next, the acceptance marked the start of the substantive review of safety and efficacy. The FDA action goal date, which is based on the original submission date in February, has been set for mid-December of this year. In the interim, our regulatory and clinical teams will focus on being responsive to the FDA during the review. Turning to slide eight, on our first quarter, In our first quarter, the prescription demand results were aligned with the expectations that were set on our last call. As a reminder, our objective in 2023 is to stabilize demand trends in our current business with a reduced commercial footprint while preserving the necessary capabilities and creating an efficient deployment of resources to support a successful launch of Xhance for CS in 2024. In the first quarter of 2023, there were approximately 30,400 new prescriptions for ex-hands, an increase of 3% compared to first quarter of 2022, while a market, which is defined by INS prescriptions written by any physician for any condition, a quite large component of which are prescriptions for allergic rhinitis, increased 8% over the same period. In addition, there were 84,400 total prescriptions for ex-hands in the first quarter of 2023. an increase of 1% compared to first quarter 2022, while the market, which again includes INS prescriptions written by any physician for any condition, a large component of which are prescriptions for allergic rhinitis, increased 5% over the same period. Results were mixed for breadth and depth of physician prescribing as measured by the total number of physicians who have patients filling ex-hance prescriptions. Regarding breadth, in the first quarter of 2023, There were 8,545 physicians who had a patient fill at least one prescription for ex-hance, an increase of 6% compared to the first quarter of 2022. Regarding depth, the number of physicians who had more than 15 ex-hance prescriptions filled by their patients in a quarter was generally unchanged at approximately 1,400 physicians, a decrease of 1% from first quarter 2022 to first quarter 2023. I'd like to note that all the data on this slide is estimated based on monthly prescription data from third parties and in large part, also on data directly reported to us by pharmacies that are part of the enhanced preferred pharmacy network. I will note that the first quarter 2022 data we're showing today reflects our current 2023 methodology. For reference, we footnoted our prior estimates based on prior methodology. While our best estimates may indicate slight growth in prescription demand, we believe stable is an appropriate way to describe these results. I'll now turn the call over to Jonathan to discuss our first quarter financial performance.
spk09: Thank you, Rami. Turning to slide 10. Our first quarter 2023 financial results are largely in line with the expectations we communicated on our last earnings call and are shaped by our strategy to prioritize capital resources for the potential launch of Exhance's first-ever FDA-approved drug treatment for chronic sinusitis. As we reported this morning, Optinoz recognized $24.5 million of SG&A plus R&D expenses in the first quarter of 2023, or approximately a $10 million decrease compared to first quarter 2022 expenses of $34.1 million. Regarding revenue, Optinoz recognized $11.8 million of Exance net revenue in the first quarter of 2023, a decrease compared to first quarter 2022 net revenues of $14.8 million. The over-year decrease in the first quarter is primarily the result of a decrease in unit shift and an increase in copay assistance driven by an increase in the proportion of volumes attributable to patients with commercial insurance that does not cover expense or who have not yet met the utilization management criteria of their insurer, as well as an increase in the proportion of volumes attributable to government programs, which increase gross to net deductions. While we exceeded the first quarter 2023 guidance that we gave on our last call for revenues of approximately $10 million in the first quarter, and we feel that the beat is encouraging, I'd like to note that we believe this result is not sufficient to change our expectations for the full year, which I will review in a moment. Finally, based on available prescription data purchased from third parties and on data we received directly from a preferred pharmacy network, the estimated average net revenue prescription for the first quarter of 2023 was $140, a decrease compared to $177 of estimated revenue per prescription in the first quarter of 2022. Year-over-year decrease is driven primarily by the increase across the net deductions and the decrease in the unit shift that influenced EXAMS net revenue performance. Overall, these results align with our intent to reduce use of cash in 2023, while maintaining the capabilities and resources that would be necessary to enable a successful launch and a new indication for EXAMS in 2024. Turning to slide 12, our first quarter of 2023 financial performance was in line with our prior guidance and, as a result, Our guidance for the full year of 2023 is largely unchanged. First, we are lowering our operating expense guidance to incorporate the effects of first quarter departures on stock compensation. We now expect operating expense defined as sales, general, and administrative expense, plus research and development expenses to be in the range from $88 million to $93 million, of which approximately $6 million is stock-based compensation. Previously, we expected operating expense to be in the range from $90 million to $95 million, of which approximately $8 million is stock-based compensation. Second, our expectation for ex-hance net revenue for the full year of 2023 is unchanged and is between $62 million to $68 million. It is important to note that we are not assuming revenues from a CS launch in our full year 2023 guidance. Third, with respect to ex-hance average net revenue per prescription, We expect our typical historical pattern of improvement from the first quarter through the remaining three quarters of 2023 and continue to expect our average net revenue per prescription to be approximately $200 for the full year of 2023. I will now turn the call back over to Rami for closing remarks. Rami? Thank you, Jonathan.
spk03: Before moving to Q&A, I'd like to take a moment to reiterate our clear strategic focus for this year. First, we believe achieving the first ever chronic sinusitis indication will be a crucial driver of future value for patients and for our company. It is therefore our top priority. Second, we are mindful of the importance of the cash we have today and of the potentially greater value of commercial investment following the future potential CS indication. Therefore, we have taken and will continue to take action to efficiently generate ex-hance revenue with the current indication. Third, we must prepare our organization to seize the potential opportunity created by a new chronic sinusitis indication by planning for a successful launch aimed at rapidly making the product available to millions of patients in need. With that, I'd like to thank you for your attention and open the call for questions and answers.
spk06: Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. please stand by while we compile the Q&A roster. Our first question comes from the line of Brandon Foulkes with Cantor Fitzgerald. Your line is now open.
spk02: Hi, thanks for taking my questions and congratulations on the quarter. Maybe just two from me. With that prescribing breadth growing, are these new prescribers asking questions about the CS indication? I guess any color... Well, how would you contextualize how prime the market is for CS launch? Understanding, obviously, you're not promoting CS right now, but just any color on the awareness of the CS potential approval and the awareness in the prescribing community versus how much sort of work would need to be done post-approval. And then maybe just secondly, any color on how the 140 net revenue per Rx compares to your expectations for 1Q given the guidance? Thank you.
spk03: I'll take the first part of that, Jonathan, and then turn the second part over to you. So with regard to prescriber expectations, I think we would characterize the change in prescriber breadth as a relative stability compared to the previous year rather than sort of a material growth. It is true that anecdotally we do get occasional questions about the chronic sinusitis future indication. And we do occasionally get questions, of course, about the clinical trials which have been completed and which are pending publication in the peer review literature. But by and large, the bulk of the prescribing universe is not yet aware of the chronic sinusitis indication and clinical trial data. And the investment that we will make in sort of making the prescribing universe aware of that is still to come.
spk09: So then, Brandon, on the second question regarding the $140 on revenue per prescription and how that compared to our expectations, I think we didn't set an explicit expectation for revenue per TRX in the first quarter. We did set an expectation for approximately $10 million in enhanced net revenues for the period. But I think that the $140 was aligned with our thinking about how the quarter would shape up. As a reminder, the last couple of years, what we anticipated at the start of the year, I think 21 and 22, we expected first quarter revenues to be, I think, 130 to 150 the one year, 140 to 160 the next year. And I think given our expectations around there being a little bit more aggressive management of inventory, quicker return to kind of summer levels, this year, because of the rising interest rate environment, Yeah, I think that 140 is best described as being in line with our expectations.
spk02: Thank you to you both. Maybe just one follow-up, if I may. Any change in how we should think about the seasonality this year of exempt prescriptions?
spk03: Yeah, Brandon, thank you for asking that. I don't think we have sufficient evidence at this point in the year to believe there will be a material change in sort of the historical cadence of our revenue over the course of the year. As we noted earlier, the first quarter is traditionally light on revenue, although the prescription demand isn't proportionately light because, as you were discussing, it's related in large part to changes in the average net revenue per prescription. And then we have historically seen a significant increase in second quarter bit of a nadir in third quarter, a bit of a softening maybe in third quarter, especially during the summer, and then sort of stronger performance in the latter part of the year. So I don't expect the pattern to change from historical trends.
spk10: Brad, thanks for taking my question.
spk09: I'll add in, I think, you know, roundly speaking, I think largely to the demand, you know, factors around seasonality. Yeah, I think in terms of, you know, the cadence on revenue per prescription is, you know, patients, you know, the primary driver there being as patients, you know, fill their, you know, out-of-pocket minimums in the early part of the year. You know, what we typically see is, you know, first quarter is kind of the low point on revenue per prescription, a strong return to, you know, something that looks like our, you know, past our average for the year in second quarter. And we sort of maintain that for the remainder of the year with a little bit, you know, a little bit of pressure at the year end to accrue for channel inventory liabilities. So I think our historical experience is how we're thinking about how, you know, revenue should progress for the year.
spk11: Great. Thank you for the color and congrats on the progress. Thanks, man.
spk06: Thank you. Our next question comes from the line of David Amsterdam with Piper Sandler. Your line is now open.
spk04: Hi, thanks. This is Skylar on for David. Can you talk about what kind of dialogue, if any, you've had with payers regarding the CS data and how you think the payer landscape will evolve with the wider label in place? Do you expect that we will see a significant shift in the payer landscape after the label expansion?
spk03: Hi, and thank you for the question. It's a little premature for us to have confidence in exactly how that will shape up. And of course, we can't speak in advance to decisions that haven't yet been made by different payers. But, you know, we're beginning really and have been for a little while now to approach this issue with various payers. And as we've said before, in many of our payer contracts, the existing language already accounts for all FDA-approved indications. Of course, today that refers only to the indication of chronic rhinosinusitis with nasal polis, but in future that would encompass a new approval for a new indication. So, you know, we have reasonable confidence that we'll have stability in our payer coverage, but we can't be certain until we get closer to the actual launch date and see how decisions pan out.
spk04: Got it. So then a quick follow-up. For the net revenue per prescription, do you think that might evolve in the context of the wider label with CF?
spk03: I don't think we have any reason to believe that our net revenue per prescription will be materially impacted. by the new indication. The primary effect that we expect from the new indication is the ability to access a much, much larger patient population within a similar number of physicians that are in our current called-on universe, and then hopefully our ability to access the incremental patients outside our current called-on universe by another mechanism.
spk04: Thanks. And if I could just add one more. What would the sales force headcount look like if you did or didn't have the co-promote partner in place? in terms of expanding to CS? Do you expect a big increase in headcount?
spk03: I can tell you that today we have 77 sales territories. I can't really speak to the number of sales territories that we would expect to have in the context of a primary care promotional partner because that may vary depending on what kind of primary care promotional partner we've engaged with. So it's sort of a TBD at this point.
spk05: All right, got it. Thanks for the color. Thank you.
spk06: And I'm currently showing no further questions at this time. I'd like to hand the call back over to Rami Mahmood for closing remarks.
spk03: In conclusion, I think we have shown you information today reflecting first quarter performance that's entirely in line with the expectations we set for the first quarter. And we intend to continue to meet the expectations that we've set as we progress onward through this year with a sense of optimism about the future approval as we enter into next year. Thank you again for joining this morning, and we'll look forward to speaking with you again in a few more months.
spk06: This concludes today's conference call. Thank you for participating. You may now disconnect. you Thank you.
spk00: Thank you. Bye. music music
spk06: Good day, and thank you for standing by. Welcome to the Optinose first quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jonathan Mealy, Vice President, Investor Relations. Please go ahead.
spk09: Good morning, and thank you for joining us today as we review Opti-Nose's first quarter 2023 performance and our plans for the remainder of the year. I'm joined today by our CEO, Dr. Rami Mahmoud, and our Chief Commercial Officer, Paul Spence. The slides that will be presented on this call can be reviewed on our website, optinose.com, in the investor section. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements. All statements that are not historical facts are hereby identified as forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated by such statements. Additional information regarding these factors and forward-looking statements is discussed under the Cautionary Note on Forward-Looking Statements section of the earnings release that we issued today. as well as under the risk factors section and elsewhere in Opti-Nose's most recent form 10-K and 10-Qs that are filed with the SEC and available at their website, sec.gov, and on our website at optinose.com. Your caution not to place undue reliance on forward-looking statements. Forward-looking statements during this conference call speak only as of the original date of this call or any earlier date indicated in such statement, and we undertake no obligation to update or revise any of these statements. We will now make prepared remarks, and then we will move to a question-and-answer session. With that, I will now turn the call over to Rami. Great.
spk03: Thank you, Jonathan, and thank you to everyone listening for joining us this morning. We appreciate you joining us for this first quarter update. Starting on slide three, we'll go into more detail in a moment, but I'd like to highlight three key takeaways from today's presentation. First, we remain enthusiastic about the potential value of a first and only new indication to treat patients who have chronic sinusitis. Claims data suggest that CS is currently being diagnosed by healthcare providers approximately 10 times more frequently than nasal polyps. In the current healthcare environment, where off-label use is increasingly constrained by payers, we believe the new indication could enable us to access a multi-fold larger patient audience and therefore drive significant growth. Second, last week we announced that the FDA accepted our supplemental new drug application for the new indication for ex-hands. In simple terms, the acceptance signals that a review of our application will proceed and that a goal date is set for December by which the FDA will aim to communicate a decision. Third, in the first quarter of the year, we continued to execute against our previously communicated strategy to prioritize the value of a potential launch of XANTS as the first ever FDA-approved drug treatment for CS. There are important differences, including patient prevalence, frequency of diagnosis, and payer dynamics that we believe make the potential for return on investment from promotion of Exhance following the label expansion into chronic sinusitis significantly greater than the return available from promotion of Exhance as a treatment for nasal polyps. Because of this, as we advised in our last update, we've structured our business to reduce use of cash in 2023 and increase focus on profitability while preserving infrastructure and capabilities that will be necessary for a successful launch of the chronic sinusitis indication in 2024. In the first quarter, we adhered to this strategic intent and delivered results that met the expectations that we set in the previous call and which keep us on track to meet our expectations for the full year. Turning to slide four. We believe a future approval of Xhance as the first and only FDA approved treatment for CS has potential to increase the number of patients for whom the product can be promoted by tenfold because claims data suggest that that order of magnitude, more patients are currently diagnosed and treated for chronic sinusitis than are diagnosed and treated for nasal polyps. We expect the greatly expanded universe of potential patients to include many who are currently cared for by physicians in our existing commercial footprint, significantly growing our potential within the scope of our current activities. We also expect the expanded universe of patients to include patients who are cared for by physicians outside of our current commercial reach. We are exploring commercial partnerships, alternative selling models, and other ways to facilitate future outreach to those physicians and patients. Turning to slide six. Last week, we announced that the FDA accepted our supplemental new drug application in pursuit of an additional ex-hance indication for treatment of patients with chronic rhinosinusitis. This is a novel indication for which the agency had never previously approved a product. Focusing on what's next, the acceptance marked the start of the substantive review of safety and efficacy. The FDA action goal date, which is based on the original submission date in February, has been set for mid-December of this year. In the interim, our regulatory and clinical teams will focus on being responsive to the FDA during the review. Turning to slide eight. On our first quarter, In our first quarter, the prescription demand results were aligned with the expectations that were set on our last call. As a reminder, our objective in 2023 is to stabilize demand trends in our current business with a reduced commercial footprint while preserving the necessary capabilities and creating an efficient deployment of resources to support a successful launch of ExHance for CS in 2024. In the first quarter of 2023, there were approximately 30,400 new prescriptions for ex-hands, an increase of 3% compared to first quarter of 2022, while a market which is defined by INS prescriptions written by any physician for any condition, a quite large component of which are prescriptions for allergic rhinitis, increased 8% over the same period. In addition, there were 84,400 total prescriptions for ex-hands in the first quarter of 2023. an increase of 1% compared to first quarter 2022, while the market, which again includes INS prescriptions written by any physician for any condition, a large component of which are prescriptions for allergic rhinitis, increased 5% over the same period. Results were mixed for breadth and depth of physician prescribing as measured by the total number of physicians who have patients filling ex-hance prescriptions. Regarding breadth, in the first quarter of 2023, there were 8,545 physicians who had a patient fill at least one prescription for ex-hance, an increase of 6% compared to the first quarter of 2022. Regarding depth, the number of physicians who had more than 15 ex-hance prescriptions filled by their patients in a quarter was generally unchanged at approximately 1,400 physicians, a decrease of 1% from first quarter 2022 to first quarter 2023. I'd like to note that all the data on this slide is estimated based on monthly prescription data from third parties and, in large part, also on data directly reported to us by pharmacies that are part of the Ex-Hance Preferred Pharmacy Network. I will note that the first quarter 2022 data we're showing today reflects our current 2023 methodology. For reference, we footnoted our prior estimates based on prior methodology. While our best estimates may indicate slight growth in prescription demand, We believe stable is an appropriate way to describe these results. I'll now turn the call over to Jonathan to discuss our first quarter financial performance.
spk09: Thank you, Rami. Turning to slide 10. Our first quarter 2023 financial results are largely in line with the expectations we communicated on our last earnings call and are shaped by our strategy to prioritize capital resources for the potential launch of Exhance's first-ever FDA-approved drug treatment for chronic sinusitis. As we reported this morning, OptiNose recognized $24.5 million of SG&A plus R&D expenses in the first quarter of 2023, or approximately a $10 million decrease compared to first quarter 2022 expenses of $34.1 million. Regarding revenue, OptiNose recognized $11.8 million of Exance net revenue in the first quarter of 2023, a decrease compared to first quarter 2022 net revenues of $14.8 million. The year-over-year decrease in the first quarter is primarily the result of a decrease in unit shift and an increase in copay assistance driven by an increase in the proportion of volumes attributable to patients with commercial insurance that does not cover expense or who have not yet met the utilization management criteria of their insurer, as well as an increase in the proportion of volumes attributable to government programs, which increase gross to net deductions. While we exceeded the first quarter 2023 guidance that we gave on our last call for revenues of approximately $10 million in the first quarter, and we feel that the beat is encouraging, I'd like to note that we believe this result is not sufficient to change our expectations for the full year, which I will review in a moment. Finally, based on available prescription data purchased from third parties and on data we received directly from a preferred pharmacy network, the estimated average net revenue prescription for the first quarter of 2023 was $140, a decrease compared to $177 of estimated revenue per prescription in the first quarter of 2022. Year-over-year decrease is driven primarily by the increase in gross net deductions and the decrease in the unit shift that influenced Ex-Ans' net revenue performance. Overall, these results align with our intent to reduce use of cash in 2023, while maintaining the capabilities and resources that would be necessary to enable a successful launch and a new indication of Tor Ex-Ans in 2024. Turning to slide 12, our first quarter of 2023 financial performance was in line with our prior guidance and, as a result, Our guidance for the full year of 2023 is largely unchanged. First, we are lowering our operating expense guidance to incorporate the effects of first quarter departures on stock compensation. We now expect operating expense defined as sales, general and administrative expense, plus research and development expenses to be in the range from $88 million to $93 million, of which approximately $6 million is stock-based compensation. Previously, we expected operating expense to be in the range from $90 million to $95 million, of which approximately $8 million is stock-based compensation. Second, our expectation for ex-hance net revenue for the full year of 2023 is unchanged and is between $62 million to $68 million. It is important to note that we are not assuming revenues from a CS launch in our full year 2023 guidance. Third, with respect to ex-hance average net revenue per prescription, We expect our typical historical pattern of improvement from the first quarter through the remaining three quarters of 2023 and continue to expect our average net revenue per prescription to be approximately $200 for the full year of 2023. I will now turn the call back over to Rami for closing remarks. Rami? Thank you, Jonathan.
spk03: Before moving to Q&A, I'd like to take a moment to reiterate our clear strategic focus for this year. First, we believe achieving the first ever chronic sinusitis indication will be a crucial driver of future value for patients and for our company. It is therefore our top priority. Second, we are mindful of the importance of the cash we have today and of the potentially greater value of commercial investment following the future potential CS indication. Therefore, we have taken and will continue to take action to efficiently generate expense revenue with the current indication. Third, we must prepare our organization to seize the potential opportunity created by a new chronic sinusitis indication by planning for a successful launch aimed at rapidly making the product available to millions of patients in need. With that, I'd like to thank you for your attention and open the call for questions and answers.
spk06: Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. please stand by while we compile the Q&A roster. Our first question comes from the line of Brandon Foulkes with Cantor Fitzgerald. Your line is now open.
spk02: Hi, thanks for taking my questions, and congratulations on the quarter. Maybe just two from me. With that prescribing breadth growing, are these new prescribers asking questions about the CS indication? I guess any color... Well, how would you contextualize how prime the market is for a CS launch? Understanding, obviously, you're not promoting CS right now, but just any color on the awareness of the CS potential approval and the awareness in the prescribing community versus how much sort of work would need to be done post-approval. And then maybe just secondly, any color on how the 140 net revenue per Rx compares to your expectations for 1Q given the guidance? Thank you.
spk03: I'll take the first part of that, Jonathan, and then turn the second part over to you. So with regard to prescriber expectations, I think we would characterize the change in prescriber breadth as a relative stability compared to the previous year rather than sort of a material growth. It is true that anecdotally we do get occasional questions about the chronic sinusitis future indication. And we do occasionally get questions, of course, about the clinical trials which have been completed and which are pending publication in the peer review literature. But by and large, the bulk of the prescribing universe is not yet aware of the chronic sinusitis indication and clinical trial data. And the investment that we will make in sort of making the prescribing universe aware of that is still to come.
spk09: So then, Brandon, on the second question regarding the $140 on revenue per prescription and how that compared to our expectations, I think we didn't set an explicit expectation for revenue per TRX in the first quarter. We did set an expectation for approximately $10 million in enhanced net revenues for the period. But I think that the $140 was aligned with our thinking about how the quarter would shape up. As a reminder, the last couple of years, what we anticipated at the start of the year, I think 21 and 22, we expected first quarter revenues to be, I think, 130 to 150 the one year, 140 to 160 the next year. And I think given our expectations around there being a little bit more aggressive management of inventory, quicker return to kind of summer levels, this year, because of the rising interest rate environment, Yeah, I think that 140 is best described as being in line with our expectations.
spk02: Thank you to you both. Maybe just one follow-up, if I may. Any change in how we should think about the seasonality this year of exempt prescriptions?
spk03: Yeah, Brandon, thank you for asking that. I don't think we have sufficient evidence at this point in the year to believe there will be a material change in sort of the historical cadence of our revenue over the course of the year. As we noted earlier, the first quarter is traditionally light on revenue, although the prescription demand isn't proportionately light because, as you were discussing, it's related in large part to changes in the average net revenue per prescription. And then we have historically seen a significant increase in second quarter revenue bit of a nadir in third quarter, a bit of a softening maybe in third quarter, especially during the summer, and then sort of stronger performance in the latter part of the year. So I don't expect the pattern to change through historical trends.
spk09: I'll add in, I think, roundly speaking, I think largely to the demand factors around seasonality. Yeah, I think in terms of, you know, the cadence on revenue per prescription is, you know, patients, you know, the primary driver there being as patients, you know, fill their, you know, out-of-pocket minimums in the early part of the year. You know, what we typically see is, you know, first quarter is kind of the low point on revenue per prescription, a strong return to, you know, something that looks like our, you know, past our average for the year in second quarter. And we sort of maintain that for the remainder of the year with a little bit, you know, a little bit of pressure at the year end to accrue for channel inventory liabilities. So I think our historical experience is how we're thinking about how, you know, revenue should progress for the year.
spk11: Great. Thank you for the color and congrats on the progress. Thanks.
spk06: Thank you. Our next question comes from the line of David Amsterdam with Piper Sandler. Your line is now open.
spk04: Hi, thanks. This is Skylar on for David. Can you talk about what kind of dialogue, if any, you've had with payers regarding the CS data and how you think the payer landscape will evolve with the wider label in place? Do you expect that we will see a significant shift in the payer landscape after the label expansion?
spk03: Hi, and thank you for the question. It's a little premature for us to have confidence in exactly how that will shape up. And of course, we can't speak in advance to decisions that haven't yet been made by different payers. But, you know, we're beginning really and have been for a little while now to approach this issue with various payers. And as we've said before, in many of our payer contracts, the existing language already accounts for all FDA-approved indications. Of course, today that refers only to the indication of chronic rhinosinusitis with nasal polyps, but in future that would encompass a new approval for a new indication. So, you know, we have reasonable confidence that we'll have stability in our payer coverage, but we can't be certain until we get closer to the actual launch date and see how decisions pan out.
spk04: Got it. So then a quick follow-up. For the net revenue per prescription, do you think that might evolve in the context of the wider label with CF?
spk03: I don't think we have any reason to believe that our net revenue per prescription will be materially impacted. by the new indication. The primary effect that we expect from the new indication is the ability to access a much, much larger patient population within a similar number of physicians that are in our current called-on universe, and then hopefully our ability to access the incremental patients outside our current called-on universe by another mechanism. Got it.
spk04: Thanks. And if I could just add one more. What would the sales force headcount look like if you did or didn't have the co-promote partner in place? in terms of expanding to CS? Do you expect a big increase in headcount?
spk03: I can tell you that today we have 77 sales territories. I can't really speak to the number of sales territories that we would expect to have in the context of a primary care promotional partner because that may vary depending on what kind of primary care promotional partner we've engaged with. So it's sort of a TBD at this point.
spk05: All right, got it. Thanks for the color.
spk06: Thank you. And I'm currently showing no further questions at this time. I'd like to hand the call back over to Rami Mahmood for closing remarks.
spk03: In conclusion, I think we've shown you information today reflecting first quarter performance that's entirely in line with the expectations we set for the first quarter. And we intend to continue to meet the expectations that we've set as we progress onward through this year with a sense of optimism about the future approval as we enter into next year. Thank you again for joining this morning, and we'll look forward to speaking with you again in a few more months.
spk06: This concludes today's conference call. Thank you for participating. You may now disconnect.
Disclaimer